ENLIVEN THERAPEUTICS INC (ELVN)
US29337E1029 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 100.14M | 75.54M | 48.31M | 47.70M | 4.94M | |||
| Marketable Securities | 153.01M | N/A | 41.97M | 40.52M | 23.97M | |||
| Other Current Assets | 13.00M | 2.22M | 2.42M | 2.18M | 1.72M | |||
| Total Current Assets | 266.15M | 77.75M | 92.70M | 90.41M | 30.62M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.06M | 1.52M | 780.00K | 350.00K | 440.00K | |||
| Other Non-Current Assets | 4.65M | 4.03M | 180.00K | 90.00K | 2.23M | |||
| Total Non-Current Assets | 5.72M | 5.55M | 950.00K | 430.00K | 2.68M | |||
| TOTAL ASSETS | 271.87M | 83.30M | 93.65M | 90.84M | 33.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 15.36M | 6.60M | 4.85M | 4.28M | 2.54M | |||
| Accounts Payable | 532.00K | 3.12M | 2.36M | 1.97M | 1.66M | |||
| Other Current Liabilities | 10.00M | N/A | N/A | N/A | N/A | |||
| Total Current Liabilities | 25.89M | 9.72M | 7.21M | 6.25M | 4.20M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 67.00K | 660.00K | 410.00K | 160.00K | 180.00K | |||
| Total Non-Current Liabilities | 67.00K | 650.00K | 410.00K | 160.00K | 180.00K | |||
| TOTAL LIABILITIES | 25.96M | 10.37M | 7.62M | 6.41M | 4.38M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -154.45M | -82.86M | -147.50M | -96.11M | -54.75M | |||
| Additional Paid In Capital | 400.17M | 6.04M | 233.52M | 180.53M | 5.87M | |||
| Common Shares | 41.00K | 149.75M | 30.00K | 20.00K | 77.76M | |||
| Other Shareholders' Equity | 141.00K | N/A | -20.00K | 0.00 | 30.00K | |||
| Shares Outstanding | 41.35M | 3.57M | 6.57M | 4.39M | 4.14M | |||
| Tangible Book Value per Share | 5.95 | -21.52 | 13.09 | 19.23 | -11.80 | |||
| Total Shareholders' Equity | 245.91M | 72.92M | 86.03M | 84.44M | 28.92M | |||
| TOTAL LIABILITIES AND EQUITY | 271.87M | 83.30M | 93.65M | 90.84M | 33.30M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 10.28 | 8.00 | 12.86 | 14.47 | 7.29 | |||
| Return On Assets (ROA) | -26.33% | 1.79% | -54.86% | -54.18% | -70.45% | |||
| Return On Equity (ROE) | -29.11% | 2.04% | -59.72% | -58.29% | -81.12% | |||
All data in USD